CD4 and celiac disease: In order to understand the optimal TCRbeta2+/TCRbeta1+ ratio at the cellular level that could provide a safe cut-off between benign and malignant T-cell populations in clinical practice, we set out to determine the physiological TRBC2/TRBC1 transcript ratio, analyzing a publicly available CD4+ T-cell RNAseq dataset (Table 3; Supplementary Table S1) [23] and an in-house dataset of duodenal T-cells from celiac disease patients and healthy donors [22].